ArticleBMC psychiatry2025
Hepatic function is associated with cognitive function in patients with stable schizophrenia.
Article in BMC psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundThe liver-brain axis, mediated by inflammatory cytokines, metabolic byproducts, and oxidative stress, shares pathological pathways with schizophrenia neurobiology. Despite this overlap, direct clinical evidence linking hepatic function indicators to psychiatric symptoms or cognitive function in schizophrenia remains limited. Therefore, this study investigated associations between clinical hepatic function indicators and both psychiatric symptoms and cognitive performance in individuals with stable schizophrenia.
methodsA cross-sectional study was conducted among 170 inpatients with clinically stable schizophrenia. Liver function indicators were obtained from fasting venous blood samples. Psychiatric symptoms were assessed using the Positive and Negative Syndrome Scale (PANSS), and cognitive function was assessed with the Montreal Cognitive Assessment–Chinese version (MoCA-C). Multiple linear regression models, adjusted for covariates, were used to examine associations between hepatic indicators and outcomes (PANSS total/subscale scores; MoCA-C total score).
resultsAfter covariate adjustment, total bilirubin (TBil) (β = 0.29, 95% CI: 0.08–0.51; P = 0.008) and indirect bilirubin (IDBil) (β = 0.48, 95% CI: 0.17–0.80; P = 0.003) were significantly positively associated with MoCA-C scores. No significant associations were observed between any hepatic indicators and PANSS total/subscale scores.
conclusionsIn this cross-sectional study of clinically stable schizophrenia, higher TBil and IDBil levels were associated with better cognitive performance. These findings suggest a potential role of bilirubin metabolism in cognitive function in schizophrenia, highlighting the need for further investigation into its relevance for cognitive impairment management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.